Fitusiran Approval(Qfitlia): March 2025 Marks a New Era in Hemophilia Treatment
Brand name: QfitliaGeneric name: fitusiranDosage form: InjectionDrug class : Antithrombin-targeting siRNA Introduction : In March 2025, a historic breakthrough was made in the world of rare diseases – the US FDA officially approved Fitusiran approval for the treatment of hemophilia A and B, with and without inhibitors. The approval was long-awaited due to the drug’s revolutionary RNA interference …